.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK05_Ipragliflozin.Ipragliflozin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK05_Ipragliflozin.Ipragliflozin| name: | Ipragliflozin |
| ATC code: | A10BK05 | route: | oral |
| n-compartments | 1 |
Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus. It facilitates urinary glucose excretion and helps lower blood glucose levels. Ipragliflozin is approved and used in several countries for the management of type 2 diabetes.
Pharmacokinetic parameters reported for healthy adult subjects following single-dose oral administration.
Kadokura, T, et al., & Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. Clinical pharmacokinetics 53(11) 975–988. DOI:10.1007/s40262-014-0180-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/25316572
Oliva, RV, & Bakris, GL (2014). Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. Journal of the American Society of Hypertension : JASH 8(5) 330–339. DOI:10.1016/j.jash.2014.02.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24631482
Kadokura, T, et al., & Kageyama, S (2014). Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. Diabetes research and clinical practice 106(1) 50–56. DOI:10.1016/j.diabres.2014.07.020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25149596